(Q38315670)

2 September 2017

1 reference

title

The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma (English)

1 reference

2 September 2017

1 reference

David A Liebner

1

1 reference

PubMed ID

25581912

2 September 2017

language of work or name

1 reference

8 January 2015

1 reference

Journal of Surgical Oncology

2 September 2017

1 reference

2 September 2017

111

1 reference

2 September 2017

5

1 reference

2 September 2017

622-631

1 reference

Trends in survival for patients with metastatic soft-tissue sarcoma

2 September 2017

1 reference

Mitosis-targeted anti-cancer therapies: where they stand.

21 January 2018

1 reference

Doxorubicin pathways: pharmacodynamics and adverse effects

21 January 2018

1 reference

Dose response evaluation of adriamycin in human neoplasia

21 January 2018

1 reference

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis

21 January 2018

1 reference

Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma

21 January 2018

1 reference

Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas

21 January 2018

1 reference

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

21 January 2018

1 reference

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

21 January 2018

1 reference

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients

21 January 2018

1 reference

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

21 January 2018

1 reference

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

21 January 2018

1 reference

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

21 January 2018

1 reference

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

21 January 2018

1 reference

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

21 January 2018

1 reference

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

21 January 2018

1 reference

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

21 January 2018

1 reference

Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity

21 January 2018

1 reference

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.

21 January 2018

1 reference

Phase II trial of paclitaxel in patients with soft-tissue sarcoma

21 January 2018

1 reference

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.

21 January 2018

1 reference

Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.

21 January 2018

1 reference

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study

21 January 2018

1 reference

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial

21 January 2018

1 reference

Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.

21 January 2018

1 reference

Cellular pharmacology of gemcitabine

21 January 2018

1 reference

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

21 January 2018

1 reference

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma

21 January 2018

1 reference

Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment

21 January 2018

1 reference

International collaboration is feasible in trials for rare conditions: the EURAMOS experience

21 January 2018

1 reference

A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma

21 January 2018

1 reference

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study

21 January 2018

1 reference

Phase I study of irinotecan in pediatric patients with malignant solid tumors

21 January 2018

1 reference

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

21 January 2018

1 reference

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.

21 January 2018

1 reference

Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study

21 January 2018

1 reference

The curability of Ewing's endothelioma of bone in children

21 January 2018

1 reference

Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

The therapy of osteogenic sarcoma: Current status and thoughts for the future

21 January 2018

1 reference

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

21 January 2018

1 reference

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

21 January 2018

1 reference

Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.

21 January 2018

1 reference

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.

21 January 2018

1 reference

The Intergroup Rhabdomyosarcoma Study-I. A final report

21 January 2018

1 reference

Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98.

21 January 2018

1 reference

Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma

21 January 2018

1 reference

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

21 January 2018

1 reference

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

21 January 2018

1 reference

External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma

21 January 2018

1 reference

A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients

21 January 2018

1 reference

Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy

21 January 2018

1 reference

Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets

21 January 2018

1 reference

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

21 January 2018

1 reference

Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy

21 January 2018

1 reference

Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations

21 January 2018

1 reference

FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2014

1 reference

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

21 January 2018

1 reference

Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline

21 January 2018

1 reference

Multimodality therapy for advanced or metastatic sarcoma

21 January 2018

1 reference

Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound

21 January 2018

1 reference

Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy

21 January 2018

1 reference

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies

21 January 2018

1 reference

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

21 January 2018

1 reference

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

21 January 2018

1 reference

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

21 January 2018

1 reference

Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma

21 January 2018

1 reference

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

21 January 2018

1 reference

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial

21 January 2018

1 reference

Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of P

21 January 2018

1 reference

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

21 January 2018

1 reference

Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma

21 January 2018

1 reference

Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma

21 January 2018

1 reference

Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

21 January 2018

1 reference

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

21 January 2018

1 reference

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

21 January 2018

1 reference

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group

21 January 2018

1 reference

Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis

21 January 2018

1 reference

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

21 January 2018

1 reference

Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy

21 January 2018

1 reference

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

21 January 2018

1 reference

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

Postoperative Nomogram for 12-Year Sarcoma-Specific Death

21 January 2018

1 reference

A competing-risks nomogram for sarcoma-specific death following local recurrence

21 January 2018

1 reference

Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.23866

1 reference

2 September 2017

1 reference

PubMed ID

25581912